{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T02:51:41Z","timestamp":1774234301780,"version":"3.50.1"},"reference-count":31,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2024,5,24]],"date-time":"2024-05-24T00:00:00Z","timestamp":1716508800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background and Objectives: Antiretroviral therapy (ART) has revolutionized the management of HIV infection, transforming it from a once-debilitating disease to a chronic, manageable condition. However, challenges such as treatment resistance, medication side effects, and long-term tolerability persist, prompting the exploration of novel therapeutic approaches. We aimed to highlight the characteristics and related comorbidities of HIV\/AIDS cases in which the antiretroviral therapy was modified. Material and Methods: A cross-sectional clinical investigation was conducted on adults diagnosed with HIV\/AIDS who were hospitalized at the \u201cSt. Parascheva\u201d Clinical Hospital of Infectious Diseases in Iasi in the Northeastern region of Romania. The timeframe under investigation was 1 January 2023 to 30 June 2023. Results: In the Northeastern part of Romania, from a total of 1692 patients in the active records, there were a total of 148 recorded cases of antiretroviral therapy switch in HIV-infected patients. The main reason for the ART switch was the simplification of the ART regimen (82 cases, 55.40%), viro-immunological failure (16 cases, 10.66%), other disturbances correlated to the ART regimen, dyslipidemia (34 cases 22.97%), depression (3 cases, 2.02%), suicide attempt (1 case, 0.67%), new situations, including the appearance of pregnancy (3 cases 2.02%), and tuberculosis (9 cases, 6.08%). ART before the switch was represented by protease inhibitors that accounted for 84 cases (56.75%) of the ART switch. Following the therapy switch, integrase inhibitor-based ART single-tablet regimens accounted for 43.91% (65 cases) of all changeovers, with non-nucleoside reverse transcriptase inhibitor regimens coming in second, in 63 cases, 42.66%. Conclusions: ART switch as an experimental therapy offers a promising approach to optimizing HIV treatment outcomes. By focusing on viral suppression and immune reconstitution, addressing treatment challenges, and exploring novel ARV agents, ART switch strategies aim to improve the overall health and well-being of individuals living with HIV.<\/jats:p>","DOI":"10.3390\/medicina60060854","type":"journal-article","created":{"date-parts":[[2024,5,24]],"date-time":"2024-05-24T03:46:56Z","timestamp":1716522416000},"page":"854","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Antiretroviral Therapy Switch in HIV-Infected Adults from a Regional HIV\/AIDS Center in NE Romania"],"prefix":"10.3390","volume":"60","author":[{"given":"Isabela Ioana","family":"Loghin","sequence":"first","affiliation":[{"name":"Department of Infectious Diseases, \u201cGrigore T. Popa\u201d University of Medicine and Pharmacy, 700115 Iasi, Romania"},{"name":"Department of Infectious Diseases, \u201cSt. Parascheva\u201d Clinical Hospital of Infectious Diseases, 700116 Iasi, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u0218erban Alin","family":"Rusu","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, \u201cSt. Parascheva\u201d Clinical Hospital of Infectious Diseases, 700116 Iasi, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8357-7048","authenticated-orcid":false,"given":"Andrei","family":"V\u00e2\u0163\u0103","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, \u201cGrigore T. Popa\u201d University of Medicine and Pharmacy, 700115 Iasi, Romania"},{"name":"Department of Infectious Diseases, \u201cSt. Parascheva\u201d Clinical Hospital of Infectious Diseases, 700116 Iasi, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mihaela","family":"Cobaschi","sequence":"additional","affiliation":[{"name":"Faculty of Medicine\/Clinical II Department, \u201cCarol Davila\u201d University of Medicine and Pharmacy, 050474 Bucharest, Romania"},{"name":"National Institute for Infectious Diseases \u201cProf. Dr. Matei Bal\u0219\u201d, 021105 Bucharest, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ion","family":"Cecan","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, \u201cSt. Parascheva\u201d Clinical Hospital of Infectious Diseases, 700116 Iasi, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmen","family":"Manciuc","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, \u201cGrigore T. Popa\u201d University of Medicine and Pharmacy, 700115 Iasi, Romania"},{"name":"Department of Infectious Diseases, \u201cSt. Parascheva\u201d Clinical Hospital of Infectious Diseases, 700116 Iasi, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmen Mihaela","family":"Dorob\u0103\u0163","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, \u201cSt. Parascheva\u201d Clinical Hospital of Infectious Diseases, 700116 Iasi, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,5,24]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"The ART-LINC of IeDEA Study Group (2009). Switching to second-line antiretroviral therapy in resource-limited settings: Comparison of programmes with and without viral load monitoring. AIDS, 23, 1867\u20131874.","DOI":"10.1097\/QAD.0b013e32832e05b2"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S1473-3099(10)70026-8","article-title":"Immune reconstitution inflammatory syndrome in patients starting antiretroviral therapy for HIV infection: A systematic review and meta-analysis","volume":"10","author":"Wandel","year":"2010","journal-title":"Lancet Infect Dis."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1038\/s41598-022-05816-5","article-title":"Analysis of antiretroviral therapy switch rate and switching pattern for people living with HIV from a national database in Japan","volume":"12","author":"Naito","year":"2022","journal-title":"Sci. Rep."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s12981-022-00453-4","article-title":"Determinants and reasons for switching anti-retroviral regimen among HIV-infected youth in a large township of South Africa (2002\u20132019)","volume":"19","author":"Kabarambi","year":"2022","journal-title":"AIDS Res. Ther."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2325958219867325","DOI":"10.1177\/2325958219867325","article-title":"Optimizing Antiretroviral Therapy in Treatment-Experienced Patients Living with HIV: A Critical Review of Switch and Simplification Strategies. An Opinion of the HIV Practice and Research Network of the American College of Clinical Pharmacy","volume":"18","author":"Chastain","year":"2019","journal-title":"J. Int. Assoc. Provid. AIDS Care (JIAPAC)"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Ruzicka, D.J., Kuroishi, N., Oshima, N., Sakuma, R., and Naito, T. (2019). Switch rates, time-to-switch, and switch patterns of antiretroviral therapy in people living with human immunodeficiency virus in Japan, in a hospital-claim database. BMC Infect. Dis., 19.","DOI":"10.1186\/s12879-019-4129-6"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1097\/QAD.0b013e328359590f","article-title":"Adherence to antiretroviral therapy during and after pregnancy in low-income, middle-income, and high-income countries: A systematic review and meta-analysis","volume":"26","author":"Nachega","year":"2012","journal-title":"AIDS"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1016\/S0140-6736(10)61997-6","article-title":"Effects of a mobile phone short message service on antiretroviral treatment adherence in Kenya (WelTel Kenya1): A randomised trial","volume":"376","author":"Lester","year":"2010","journal-title":"Lancet"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"S153","DOI":"10.1097\/QAD.0000000000003108","article-title":"Optimizing switching strategies to simplify antiretroviral therapy: The future of second-line from a public health perspective","volume":"35","author":"Papot","year":"2021","journal-title":"AIDS"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1080\/09540120903193708","article-title":"Factors associated with self-reported adherence to antiretroviral therapy in a Tanzanian setting","volume":"22","author":"Watt","year":"2010","journal-title":"AIDS Care"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e33429","DOI":"10.2196\/33429","article-title":"Effect of Switching Antiretroviral Treatment Regimen in Patients With Drug-Resistant HIV-1 Infection: Retrospective Observational Cohort Study","volume":"8","author":"Li","year":"2022","journal-title":"JMIR Public Health Surveill."},{"key":"ref_12","unstructured":"Collaborative Initiative for Paediatric HIV Education and Research (CIPHER) Global Cohort Collaboration (2019). Incidence of switching to second-line antiretroviral therapy and associated factors in children with HIV: An international cohort collaboration. Lancet HIV, 6, e105\u2013e115. Erratum in Lancet HIV 2020, 7, e803."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"87","DOI":"10.2147\/HIV.S348076","article-title":"Time to Switch to Second-Line Anti-Retroviral Treatment and Its Predictors Among HIV Infected Adults with Virological Failure in Northwest Ethiopia: A Retrospective Follow-Up Study","volume":"14","author":"Alemu","year":"2022","journal-title":"HIV\/AIDS-Res. Palliat. Care"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Panel on Clinical Practices for Treatment of HIV Infection (1998). Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Ann. Intern. Med., 128, 1079\u20131100.","DOI":"10.7326\/0003-4819-128-12_Part_2-199806151-00003"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1001\/jama.2022.22246","article-title":"Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2022 Recommendations of the International Antiviral Society\u2013USA Panel","volume":"329","author":"Gandhi","year":"2023","journal-title":"JAMA-J. Am. Med. Assoc."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1097\/QAI.0000000000002466","article-title":"Long-Acting Injectable Cabotegravir + Rilpivirine for HIV Maintenance Therapy: Week 48 Pooled Analysis of Phase 3 ATLAS and FLAIR Trials","volume":"85","author":"Rizzardini","year":"2020","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1016\/S0140-6736(17)31917-7","article-title":"Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial","volume":"390","author":"Margolis","year":"2017","journal-title":"Lancet"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e351","DOI":"10.1016\/S2352-3018(16)30015-7","article-title":"Efficacy and safety of contemporary dual-drug antiretroviral regimens as first-line treatment or as a simplification strategy: A systematic review and meta-analysis","volume":"3","author":"Achhra","year":"2016","journal-title":"Lancet HIV"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Plum, P.E., Maes, N., Sauvage, A.S., Frippiat, F., Meuris, C., Uurlings, F., Lecomte, M., L\u00e9onard, P., Paquot, N., and Fombellida, K. (2021). Impact of switch from tenofovir disoproxil fumarate-based regimens to tenofovir alafenamide-based regimens on lipid profile, weight gain and cardiovascular risk score in people living with HIV. BMC Infect. Dis., 21.","DOI":"10.1186\/s12879-021-06479-9"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1310\/hct1002-116","article-title":"Low-level viremia in HIV-1 infection: Consequences and implications for switching to a new regimen","volume":"10","author":"Cohen","year":"2009","journal-title":"HIV Clin. Trials"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Baril, J.G., Angel, J.B., Gill, M.J., Gathe, J., Cahn, P., van Wyk, J., and Walmsley, S. (2016). Dual Therapy Treatment Strategies for the Management of Patients Infected with HIV: A Systematic Review of Current Evidence in ARV-Naive or ARV-Experienced, Virologically Suppressed Patients. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0148231"},{"key":"ref_22","first-page":"2135","article-title":"Antiretroviral stewardship in a tertiary academic hospital: The need for a clinical pharmacist","volume":"28","author":"Bronkhorst","year":"2023","journal-title":"Health SA"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s12981-023-00544-w","article-title":"What are the determinants of antiretroviral therapy adherence among stable people living with HIV? A cross-sectional study in Cambodia","volume":"20","author":"Tuot","year":"2023","journal-title":"AIDS Res. Ther."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1097\/QAI.0000000000002135","article-title":"Effectiveness of Transmitted Drug Resistance Testing Before Initiation of Antiretroviral Therapy in HIV-Positive Individuals","volume":"82","author":"Lodi","year":"2019","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Iannone, V., Passerotto, R.A., Lamanna, F., Steiner, R.J., Lombardi, F., Salvo, P.F., Dusina, A., Farinacci, D., Borghetti, A., and Di Giambenedetto, S. (2023). Changes in Metabolic Profile in PLWHIV Switching to Doravirine-Based Regimen. Viruses, 15.","DOI":"10.3390\/v15051046"},{"key":"ref_26","unstructured":"Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission (2024, April 01). Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States, Available online: http:\/\/aidsinfo.nih.gov\/contentfiles\/lvguidelines\/PerinatalGL.pdf."},{"key":"ref_27","unstructured":"World Health Organization HIV\/AIDS Programme (2013). Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection: Recommendations for a Public Health Approach, WHO."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s40265-015-0515-6","article-title":"Modifying Antiretroviral Therapy in Virologically Suppressed HIV-1-Infected Patients","volume":"76","author":"Collins","year":"2015","journal-title":"Drugs"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"528","DOI":"10.3855\/jidc.12519","article-title":"Cumulative effects of hypertriglyceridemia in HIV-infected patients switching from NNRTIs to PI-based antiretroviral therapy","volume":"16","author":"Zhang","year":"2022","journal-title":"J. Infect. Dev. Ctries."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1093\/cid\/ciw495","article-title":"Lipid profiles and APOE4 allele impact midlife cognitive decline in HIV-infected men on antiretroviral therapy","volume":"63","author":"Mukerji","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"19542","DOI":"10.7448\/IAS.17.4.19542","article-title":"Rates of cardiovascular events and deaths are associated with advanced stages of HIV-infection: Results of the HIV HEART study 7, 5-year follow-up","volume":"17","author":"Esser","year":"2014","journal-title":"J. Int. AIDS Soc."}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/60\/6\/854\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:47:41Z","timestamp":1760107661000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/60\/6\/854"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,24]]},"references-count":31,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,6]]}},"alternative-id":["medicina60060854"],"URL":"https:\/\/doi.org\/10.3390\/medicina60060854","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,24]]}}}